ZA200605080B - Pharmaceutical compositions - Google Patents
Pharmaceutical compositionsInfo
- Publication number
- ZA200605080B ZA200605080B ZA200605080A ZA200605080A ZA200605080B ZA 200605080 B ZA200605080 B ZA 200605080B ZA 200605080 A ZA200605080 A ZA 200605080A ZA 200605080 A ZA200605080 A ZA 200605080A ZA 200605080 B ZA200605080 B ZA 200605080B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53173503P | 2003-12-22 | 2003-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200605080B true ZA200605080B (en) | 2008-06-25 |
Family
ID=34738689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200605080A ZA200605080B (en) | 2003-12-22 | 2006-06-20 | Pharmaceutical compositions |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050153999A1 (de) |
| EP (1) | EP1706116A1 (de) |
| JP (1) | JP2007515425A (de) |
| KR (1) | KR20060113737A (de) |
| CN (1) | CN1897942A (de) |
| AR (1) | AR046769A1 (de) |
| AU (1) | AU2004308935A1 (de) |
| BR (1) | BRPI0417950A (de) |
| CA (1) | CA2550432A1 (de) |
| MX (1) | MXPA06007210A (de) |
| NO (1) | NO20063393L (de) |
| PE (1) | PE20051049A1 (de) |
| PL (1) | PL380482A1 (de) |
| TW (1) | TW200531686A (de) |
| WO (1) | WO2005063243A1 (de) |
| ZA (1) | ZA200605080B (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201500027TA (en) * | 2006-04-05 | 2015-02-27 | Opko Health Inc | Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor |
| PE20080353A1 (es) * | 2006-04-05 | 2008-04-25 | Schering Corp | Sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-espiro[4,5]decan-2-ona y proceso de preparacion de las mismas |
| CL2007000945A1 (es) * | 2006-04-05 | 2008-01-25 | Schering Corp | Formulacion farmaceutica que comprende una sal cristalina de monohidrato de hidrocloruro de (5s,8s)-8-[[(1r)-1-(3,5-bistrifluorometil)fenil]-etoximetil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona; capsula que la contiene; y uso en el tratamiento de la emesis y nausea. |
| AR066191A1 (es) * | 2007-03-22 | 2009-08-05 | Schering Corp | Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona |
| AR065802A1 (es) * | 2007-03-22 | 2009-07-01 | Schering Corp | Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas |
| CA2743584A1 (en) * | 2008-11-23 | 2010-05-27 | Pfizer Inc. | Lactams as beta secretase inhibitors |
| SG178403A1 (en) * | 2009-08-14 | 2012-03-29 | Opko Health Inc | Intravenous formulations of neurokinin-1 antagonists |
| AU2014271269B2 (en) * | 2009-08-14 | 2016-11-03 | Opko Health, Inc. | Intravenous formulations of neurokinin-1 antagonists |
| RS59734B1 (sr) * | 2012-01-23 | 2020-02-28 | Sage Therapeutics Inc | Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina |
| NL2018041B1 (en) * | 2016-12-22 | 2018-06-28 | Land Life Company B V | Process to prepare a biodegradable pulp product |
| WO2020232274A1 (en) * | 2019-05-15 | 2020-11-19 | Bexson Biomedical, Inc. | Ketamine formulation for subcutaneous injection |
| WO2020259675A1 (zh) * | 2019-06-28 | 2020-12-30 | 上海盛迪医药有限公司 | 神经激肽-1拮抗剂 |
| KR20220165251A (ko) | 2020-04-03 | 2022-12-14 | 네르 쎄라퓨틱스 리미티드 | 패혈증, 패혈성 쇼크, 급성 호흡 곤란 증후군 (ards) 또는 다발성 기관 기능장애 증후군 (mods)으로부터 선택된 질환을 치료하기 위한 nk-1 수용체 길항제 |
| US11872222B2 (en) | 2020-06-02 | 2024-01-16 | Nerre Therapeutics Limited | Uses |
| JP2024501994A (ja) * | 2020-12-25 | 2024-01-17 | 上海盛迪医▲葯▼有限公司 | Ｎｋ１拮抗剤プロドラッグ化合物と５－ｈｔ３受容体拮抗剤との併用使用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2791346B3 (fr) * | 1999-03-25 | 2001-04-27 | Sanofi Sa | Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant |
| JP4334229B2 (ja) * | 2001-03-20 | 2009-09-30 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤 |
| PE20030762A1 (es) * | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
-
2004
- 2004-12-20 KR KR1020067012300A patent/KR20060113737A/ko not_active Application Discontinuation
- 2004-12-20 CA CA002550432A patent/CA2550432A1/en not_active Abandoned
- 2004-12-20 EP EP04815019A patent/EP1706116A1/de not_active Withdrawn
- 2004-12-20 AU AU2004308935A patent/AU2004308935A1/en not_active Abandoned
- 2004-12-20 AR ARP040104804A patent/AR046769A1/es not_active Application Discontinuation
- 2004-12-20 BR BRPI0417950-1A patent/BRPI0417950A/pt not_active Application Discontinuation
- 2004-12-20 WO PCT/US2004/042893 patent/WO2005063243A1/en active Application Filing
- 2004-12-20 JP JP2006545570A patent/JP2007515425A/ja not_active Withdrawn
- 2004-12-20 MX MXPA06007210A patent/MXPA06007210A/es not_active Application Discontinuation
- 2004-12-20 PL PL380482A patent/PL380482A1/pl not_active Application Discontinuation
- 2004-12-20 US US11/017,156 patent/US20050153999A1/en not_active Abandoned
- 2004-12-20 CN CNA200480038273XA patent/CN1897942A/zh active Pending
- 2004-12-20 TW TW093139690A patent/TW200531686A/zh unknown
-
2005
- 2005-01-03 PE PE2005000022A patent/PE20051049A1/es not_active Application Discontinuation
-
2006
- 2006-06-20 ZA ZA200605080A patent/ZA200605080B/xx unknown
- 2006-07-21 NO NO20063393A patent/NO20063393L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR046769A1 (es) | 2005-12-21 |
| PL380482A1 (pl) | 2007-02-05 |
| MXPA06007210A (es) | 2006-08-18 |
| NO20063393L (no) | 2006-07-21 |
| WO2005063243A1 (en) | 2005-07-14 |
| JP2007515425A (ja) | 2007-06-14 |
| PE20051049A1 (es) | 2006-01-03 |
| CN1897942A (zh) | 2007-01-17 |
| US20050153999A1 (en) | 2005-07-14 |
| BRPI0417950A (pt) | 2007-04-17 |
| TW200531686A (en) | 2005-10-01 |
| CA2550432A1 (en) | 2005-07-14 |
| AU2004308935A1 (en) | 2005-07-14 |
| EP1706116A1 (de) | 2006-10-04 |
| KR20060113737A (ko) | 2006-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0320382D0 (en) | Pharmaceutical compositions | |
| GB0327723D0 (en) | Pharmaceutical compositions | |
| GB2389530B (en) | Pharmaceutical compositions | |
| EP1765283A4 (de) | Pharmazeutische zusammensetzungen | |
| ZA200605080B (en) | Pharmaceutical compositions | |
| GB2391473B (en) | Pharmaceutical compositions | |
| HU0301154D0 (en) | Pharmaceutical composition | |
| GB0300531D0 (en) | Pharmaceutical compositions | |
| GB0300427D0 (en) | Pharmaceutical composition | |
| HK1084670A1 (en) | Pharmaceutical compositions comprising cabbinochreme type compounds | |
| EP1648411A4 (de) | Pharmazeutische zusammensetzungen | |
| GB0307866D0 (en) | Pharmaceutical composition | |
| EP1805154A4 (de) | Pharmazeutische zusammensetzungen | |
| EP1699458A4 (de) | Pharmazeutische zusammensetzung | |
| GB0329232D0 (en) | Pharmaceutical composition | |
| GB0317663D0 (en) | Pharmaceutical composition | |
| HK1093896A1 (en) | Medicinal composition | |
| HU0302441D0 (en) | Pharmaceutical compositions having antibiothic effect | |
| GB0300885D0 (en) | Pharmaceutical composition | |
| EP1655029A4 (de) | Medizinische zusammensetzungen | |
| GB0213481D0 (en) | Pharmaceutical compositions | |
| EP1600445A4 (de) | Medizinische zusammensetzung | |
| EP1480649A4 (de) | Stabile pharmazeutische zusammensetzungen | |
| GB0306933D0 (en) | Pharmaceutical composition | |
| GB0305579D0 (en) | Pharmaceutical compositions |